The CXCR4/CXCR7/CXCL12 chemokine axis plays important roles in the migration of tumor cells during cancer development by modulating site-specific distant metastasis including to regional lymph nodes. We investigated the correlation of these chemokine expressions to prognosis in lymph-node-positive non-small-cell lung cancer (NSCLC) patients. A total of 140 surgically resected specimens of primary site (PS) and metastatic lymph nodes (MLN) of NSCLC involving hilar and/or mediastinal lymph nodes (N1-2) were collected. CXCR4, CXCR7 and CXCL12 expressions were evaluated. Cox regression analysis was performed to determine whether these chemokines were independent prognostic factors in N1-2 NSCLC. High expression of CXCR4 in PS and CXCL12 in MLN was associated with poor overall survival (OS) (P = .025 and .033, respectively). Significant correlations between CXCR4 expression in PS and CXCL12 expression in MLN were observed (P = .040). There was significant difference in OS between 2 groups according to expressions of CXCR4 in PS and CXCL12 in MLN (P = .0033). Expression of CXCL12 in MLN was identified as an independent prognostic factor (HR 1.79, 95% CI 1.08-3.04, P = .023). CXCL12 in MLN was mainly expressed by tumor cells compared with stromal cells (56% vs 25%, respectively, P < .0001). CXCR4/CXCL12 may play roles in tumor progression in MLN and is associated with poor prognosis of lymph-node-positive NSCLC patients.
G-protein coupled receptor C-X-C chemokine receptor-4 (CXCR4)
have been shown to modulate site-specific distant metastasis of many cancer types. 4 C-X-C chemokine receptor-7 (CXCR7) has also been described as a second receptor for CXCL12. 5 Previous studies reported that tumor cells expressed a high level of CXCR4 and that tumor metastasis target tissues, such as lung, liver, brain and bone, expressed high levels of CXCL12. 6 Furthermore, CXCL12 induced migration of tumor cells to target organs via a CXCL12-CXCR4 chemotactic gradient. These studies have led to the current CXCL12/CXCR4 "endocrine axis" model, in which CXCR4 upregulation in metastatic cells caused metastasis towards organs that abundantly express CXCL12. 7 However, the mechanisms by which these paracrine effects impact cancer progression and the potential role of CXCL12 are still uncertain.
In general, normal lymph node tissue shows high expression of CXCL12. 4 Although CXCL12 expression in lymph node stromal cells in pre-metastatic status is considered to have an important role during the process of tumor metastasis, how CXCL12 expression in lymph nodes is altered in the post-metastatic status is unknown.
Therefore, it is important to analyze metastatic lymph nodes (MLN)
and to evaluate the change of CXCL12 expression compared with normal lymph nodes.
High expression of chemokine receptors in the primary site (PS) in cancer suggests the potential effectiveness of diagnostic agents and therapy targeted to chemokine receptor-overexpressing tumors. However, despite previous reports on chemokine receptor expression in various cancers, only a few clinical studies have been performed to evaluate the clinical significance of chemokine receptor status in NSCLC. [8] [9] [10] [11] A previous report showed that high CXCR7 mRNA level might be related to the development of lymph node metastasis in NSCLC, 8 and high CXCR4 protein expression was found to be significantly associated with lymph node metastasis, distant metastasis, tumor stage and overall survival (OS) in NSCLC. 10 In contrast, in another study, strong CXCR4-positive nuclear staining was associated with a significantly better outcome in early stage NSCLC compared with CXCR4-negative nuclear staining. 9 The CXCL12/CXCR4 axis was shown to be involved in the dissemination of NSCLC cells into the pleural space. 11 Despite these reports, no studies on chemokine receptors and chemokines in MLN in NSCLC have been described.
In this study, we hypothesized that chemokine and chemokine receptor expression in PS as well as MLN affects the prognosis of NSCLC. Here we examined CXCR4 and CXCR7 in PS and CXCL12 expressions in MLN in NSCLC patients and assessed the prognostic impact of the expressions of these factors.
| MATERIALS AND METHODS

| Patients
From November 2000 to November 2012, a total of 1194 NSCLC patients underwent surgical resection at the Department of Surgery and Science, Kyushu University Hospital, Fukuoka, Japan. Among these patients, we selected 140 patients (11.7%) with resected NSCLC with regional lymph node metastases (pathological N1 or N2). The profiles of these 140 patients are shown in Table 1 . Allred score of 0-6 was regarded as low expression, while a score of 7 and 8 was confirmed as high expression (Fig. S1 ). When multiple lymph node metastases were recognized, the lymph node with the highest expression level was used to determine the total Allred score.
IHC results were evaluated independently by 2 of the authors (MK and FS), who were blinded to the clinical data of the patients. . After thoroughly washing with PBS, the slides were mounted in DAPI (SigmaAldrich, St. Louis, MO, USA) and examined using a BZ-9000 microscope (Keyence, Osaka, Japan).
| Indirect immunofluorescence
| RT-PCR
Of the 140 total cases examined by IHC, 13 patients were exam- between low and high groups. C t , threshold cycle. DC t , C t of target À C t of reference (b-actin). The statistical difference was assessed by two-way analysis of variance. *P < .05, **P < .01, ***P < .0001
System II TP-900 (Takara Bio) using a TaqMan Gene Expression DDC t = DC t (target sample: lymph node meta) À DC t (control sample: primary lung cancer). RT-PCR assays were performed in duplicate for each sample, and the mean value was used for calculation of the mRNA expression levels. Primer sets for all genes were purchased from Takara Bio. The following primers were used:
CXCR4: Hs00976734m1, ACKR3: Hs00604567m1, CXCL12:
Hs03676656 mH and b-actin: 4310884E.
| Statistical methods
All data are expressed as the means AE SEM. Statistical analysis was performed using JMP Pro statistical software version 12.2.0 (SAS Institute, Cary, NC, USA). The OS rates after surgical treatment were To confirm our IHC index, we first analyzed the correlation between total Allred score and RT-PCR quantification. A significant correlation between total Allred score grouped by cut-off and DC t value was found (CXCR4: P < .05; CXCR7: P < .01; and CXCL12: P < .0001) (Figure 1 ).
| Protein expression of CXCR4 in primary site
and CXCR7 and CXCL12 in metastatic lymph nodes
Immunohistochemical analysis revealed CXCR4 expression in the nuclei and/or membrane of tumor cells, whereas CXCR7 expression was found in cytoplasm and/or membrane of tumor cells (Figure 2A , B and Fig. S2A,B) . CXCL12 protein was found in the cytoplasm and/ or membrane of tumor cells ( Figure 2C and Fig. S2C ). High CXCR4
protein expression was observed in 60 (42.9%) PS samples. In MLN samples, high CXCR7 and CXCL12 protein expressions were observed in 82 (58.6%) and 79 samples (56.4%) ( Figure 2D ). The isotype control for CXCL12 in MLN is shown in Fig. S2D . CXCL12 was also expressed on stromal cells in MLN (Fig. S2E ). difference between these expression rates (P < .0001). Thus, we evaluated mainly the chemokine expression in tumor cells in MLN.
| Relationships between CXCR4, CXCR7 and CXCL12 protein expression in primary site and metastatic lymph nodes with clinicopathological features
We next assessed the relationships of CXCR4, CXCR7 and CXCL12 protein expression in PS or MLN with clinicopathological features.
As shown in Table 2 , high CXCR4 protein expression in PS was significantly associated with intratumoral vascular invasion (P = .031).
Low CXCR7 protein expression in MLN was associated with histology (P = .011). High CXCL12 protein expression in MLN was not correlated with any clinicopathological features (Table 3) . Table S1 shows that high CXCR7 protein expression in PS was significantly associated with histology and histological grade (P = .012 and .027, respectively). High CXCL12 protein expression in PS was significantly associated with intratumoral lymphatic vessel invasion (P = .0031). High CXCR4 protein expression in MLN was associated 
| Comparison of total Allred scores and mRNA expression in primary site and metastatic lymph nodes
The total Allred scores of CXCR4, CXCR7 and CXCL12 in both PS and MLN are shown in Fig. S3 . The expression of CXCR4 and CXCL12 protein in MLN were significantly higher than those in PS (P < .01 and P < .0001, respectively) ( Fig. S3A,C) . Conversely, the expression of CXCR7 protein in MLN was significantly lower than that in PS (P < .05) (Fig. S3B ). Fig. S3D shows the mRNA levels of CXCR4, CXCR7 and CXCL12 both in PS and MLN. CXCL12 mRNA expression in MLN was significantly higher than that in PS (P = .0077); however, there were no significant differences in CXCR4 or CXCR7 mRNA levels between sites (P = .097 or P = .051, respectively). Kaplan-Meier analysis revealed that patients with high CXCR4 protein expression in PS had a significantly shorter OS than the group with low CXCR4 protein expression in PS (P = .025, log-rank test) ( Figure 4A ). Furthermore, the group with high CXCL12 protein expression in MLN had a significantly shorter OS than the group with low CXCL12 protein expression in MLN (P = .033, log-rank test) ( Figure 4B ). We observed significant differences between the T A B L E 4 Correlations between CXCR4 expression in the primary site and CXCR7 and CXCL12 expression in the metastatic lymph nodes High 17 (29) 43 (52) 20 (33) 40 (51) MLN, metastatic lymph nodes; PS, primary site.
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Postoperative overall survival curves of patients with non-small cell lung cancer (NSCLC) in the primary site and metastatic lymph nodes. A, Kaplan-Meier curves show overall survival according to CXCR4 in the primary site (PS). Patients with high CXCR4 expression had a poorer prognosis than patients with low CXCR4 expression (P < .05, log-rank test). B, Kaplan-Meier curves show overall survival according to CXCL12 expressions in metastatic lymph nodes (MLN). Patients with high CXCL12 expression had a poorer prognosis than patients with low CXCL12 expression (P < .05, log-rank test). C, Subgroup analysis using both CXCR4 expression in PS and CXCL12 expression in MLN. Patients with both high CXCR4 and high CXCL12 expression had a poorer prognosis than the other patient groups (P < .005) group with CXCR4 expression in PS and the group with CXCL12 expression in MLN (log-rank test, P = .0033; Figure 4C ). This result indicated that the OS was worse for patients with both high CXCR4 expression in PS and high CXCL12 expression in MLN compared with patients with high expression of CXCR4 or CXCL12 alone.
| Prognostic factors for survival of 140 nonsmall-cell lung cancer patients
Cox regression hazard regression models showed that CXCL12 expression on tumor cells in MLN (HR 1.79; 95% CI 1.08-3.04; P = .023) as well as advanced age (≥75 years) (HR 1.90; 95% CI 1.01-3.37), multiple MLN station (HR 1.86; 95% CI 1.12-3.14; P = .012) and intratumoral vascular invasion (HR 2.30; 95% CI 1.29-4.34; P = .0041) were independent prognostic factors for OS (Table 5 ).
| CXCL12 expressing cells in the primary site and metastatic lymph nodes
We next performed double immunostaining for CXCL12 and a-SMA to identify cancer-associated fibroblasts (CAF) using paraffinembedded specimens. In PS, both CXCL12 protein expression and a-SMA protein expression were predominant ( Figure 5A ). In MLN, CXCL12 protein expression was found in the membrane of tumor cells and a-SMA protein expression in the surrounding stroma. Double positive cells were seen at the border area of the tumor cluster.
In MLN, CXCL12 protein was expressed at higher levels in tumor cells than in CAF ( Figure 5B ).
| DISCUSSION
In this study, we demonstrated the prognostic impact of CXCR4 In general, normal lymph node tissue shows high expression of CXCL12. 4 Therefore, it is reasonable to suppose that CXCR4-posi- | 163
we mainly examined the expression of CXCL12 not on stromal cells but on tumor cells in metastatic lymph nodes. The verification of this hypothesis is necessary and we are now planning for further study to address these questions.
In the present study, we showed that CXCL12 expression on tumor cells in MLN was elevated both at protein and mRNA levels.
The protein expression results were consistent with mRNA expression findings for only CXCL12. One reason for this may be due to the type of antibody and/or the state of cDNA. Nevertheless, we found that the expression of CXCL12 expression in MLN was significantly higher than CXCL12 expression in PS (Fig. S3) . We also showed that CXCL12
in MLN was an independent prognostic factor for survival.
Our results support the observation that abnormal overexpression of CXCR4 is associated with worse OS in NSCLC. 26 can also promote tumor vascularization and act as a survival or growth factor. 29 We found that CXCR4 exhibited a significant positive correlation with pathological intratumoral vascular invasion (P = .031). Hence, CXCR4 in PS was an independent prognostic factor for survival. Some studies have reported that CXCR4 and CXCR7
are highly expressed in lung cancer tissue and contribute to cancer metastasis. 30, 31 Emerging evidence has demonstrated that epithelial-mesenchymal transition (EMT) plays an important role in cancer metastasis. 32 Previous studies have shown that the CXCL12-CXCR4 signal also plays an important role in EMT. 33 CAF can promote EMT by releasing CXCL12, which modulates the stability of EMT transcription factors. 34 The mechanisms underlying the upregulation of CXCL12 expression are not completely understood, although previous studies have shown that CAF stimulate tumor progression by CXCL12 secretion. 35, 36 Two major mechanisms by which fibroblast-derived CXCL12 promotes tumor progression have been identified. 37 First, CXCL12 facilitates tumor cell growth in a paracrine manner by directly stimulating tumor cell growth via CXCR4. Second, CXCL12
from CAF induces recruitment of endothelial progenitors, which allow for tumor angiogenesis (an endocrine effect of CXCL12). 37 Experimental and clinical evidence supports the role of CAF as metastasis promoters in the primary tumor, whereas the role of CAF in lymph nodes during distant metastasis is not clear. 38 Finally, one limitation of our study was the retrospective design. 
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